Analysis of the progress and market status of Mobotinib (Mobosetinib) included in medical insurance

Mobocertinib (Mobocertinib), chemical name: EXK-3514, trade name: Exkivity, is an oral tyrosine kinase inhibitor (TKI) designed to treat a specific type of non-small cell lung cancer (NSCLC). The drug specifically targets patients who carry exon 20 insertion mutations in the EGFR (epidermal growth factor receptor) gene, a rare mutation that is closely linked to the development of lung cancer.

Although Mobosetinib has been launched in China, it has not yet been included in the medical insurance directory, which makes domestic patients face certain challenges when purchasing. For more detailed information, patients are advised to consult their local hospital or pharmacy. In the international market, consumers can choose original drugs or generic drugs. Among them, original drugs, such as the Hong Kong version of Japan's Takeda Pharmaceutical products, are relatively expensive, about 7,000 to 8,000 yuan. Generic drugs mainly come from Laos and Bangladesh, and are more affordable at about more than 3,000 yuan, and their drug ingredients are highly similar to the original drugs.

Mobotinib has a unique mechanism of action. It mainly inhibits the tyrosine kinase activity of EGFR mutant protein and blocks the signal transduction pathway of cancer cells, thereby effectively inhibiting the growth and spread of cancer cells. Unlike other TKIs that target EGFR mutations, mobosetinib can target exons20Insertion mutations play a role, and such mutations often lead to resistance to existing EGFR-TKIs, so mobosetinib (mobosetinib) provides a new treatment option for these patients.

In clinical application, Mobotinib (Mobosetinib) is usually recommended to be taken orally once a day, and the specific dosage and treatment plan are personalized by doctors based on the specific conditions of the patient. However, the use of this drug may also be associated with some side effects, such as diarrhea, rash, stomatitis, abnormal liver function, and pneumonia. Therefore, during treatment, patients should be regularly monitored by their doctor so that any possible side effects can be dealt with promptly.